Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward Looking Statements

This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business, our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

The results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements include those described elsewhere in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under "Item 1A. - Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

Recent Developments

Corporate Name Change

On February 21, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Formation with the Secretary of State of Nevada to change the Company's corporate name to "BioScience Health Innovations Inc.", with an effective date of February 21, 2025. The name change was approved by the Company's Board of Directors on February 21, 2025.

Overview

As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting includes: Dementia and Alzheimer's disease, ADHD and ADD, Long Covid, General Energy, Traumatic Brain Injury, Mild Cognitive Decline, GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy.

A trend that we believe is very beneficial and encouraging is the recent growing interest in mitochondria health and the role that mitochondria dysfunction plays in mental health and physical health issues. Methylene Blue and specialty natural options has emerged as valuable foundational health options on these fronts. We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management's discussion and analysis and results of operations are based upon our accompanying financial statements for the six months ended June 30, 2026, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Note 3. Summary of Significant Accounting Policies, to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, describes the significant accounting policies and methods used in the preparation of the Company's financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

Results Of Operations

THREE MONTHS ENDED JUNE 30, 2026 COMPARED TO JUNE 30, 2025

Our net loss for the three months ended June 30, 2026 was $185,753 compared to a net income of $457,704 during the three months ended June 30, 2025. The Company has generated revenue of $1,036,364 and $1,757,463 during the three months ended June 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company's sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company also had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Expenses incurred were operating expenses of $877,365 during the three months ended June 30, 2026, compared to $616,774 during the three months ended June 30, 2025. Expenses increased as a result of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.

SIX MONTHS ENDED JUNE 30, 2026 COMPARED TO JUNE 30, 2025

Our net loss for the six months ended June 30, 2026 was $415,660, compared to a net income $884,502 during the six months ended June 30, 2025. The Company has generated revenue of $1,787,310 and $2,894,533 during the six months ended June 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company's sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Operating expenses were $1,592,868 during the six months ended June 30, 2026, compared to $1,086,121 during the six months ended June 30, 2025. Expenses increased because of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2026, our total assets were $2,136,150, consisting of cash, accounts receivable, income tax receivable, digital assets, inventory, prepaid expenses, right-of-use assets, deposits, and intangible assets. The Company's net working capital was $1,685,704 and management believes that its cash balance of $712,378 as of June 30, 2026 is sufficient to meet its obligations over the next year.

Cash Flows from Operating Activities

We have generated negative cash flows from operating activities. For the six months ended June 30, 2026, net cash flows used in operating activities was $1,093,981, consisting of our net loss of $415,660 plus changes in operating activities of $678,321. For the six months ended June 30, 2025, net cash flows providing in operating activities was $613,319, consisting of our net income of $884,502 offset by changes in operating activities of $271,183.

Cash Flows from Investing Activities

For the six months ended June 30, 2026, we had net cash used in investing activities of $26,958 in connection with the purchase of intangible assets. For the six months ended June 30, 2025, we had net cash used in investing activities of $46,064 in connection with the purchase of intangible assets.

Cash Flows from Financing Activities

For the six months ended June 30, 2026, net cash flows provided by financing activities was $1,171,392, consisting of $748,120 in advances from related parties and $773,272 of cash acquired for selling common stock, offset by repayments of related party advances of $150,000 and repayment of a related party note payable of $200,000. For the six months ended June 30, 2025, net cash flows provided by financing activities was $69,635, consisting of advances from related parties of $1,391,635 offset by repayments to related parties of $1,322,000.

PLAN OF OPERATION AND FUNDING

The BioScience Health Innovations' management team plans to focus on gaining traction for its mental health and general wellness products. Best 365 Labs, Inc has filed for a provisional patent on its mental wellness, natural products which is an additional reason we plan to focus and grow this sector of the products. With the Global Mental Health Marketplace currently valued at $383.31 billion annually and with 41 million people holding a prescription for Adderall that the market conditions are idea for us to offer our natural substitute product options (which are also unique).

As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in these potential marketplaces, through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting include:

MANAGEMENT DISCUSSION AND ANALYSIS

For the Quarter and Six Months Ended June 30, 2026 (Second Quarter 2026)

The following discussion should be read together with our unaudited financial statements and the related notes. This section contains forward-looking statements that reflect management's current expectations and are subject to risks and uncertainties. Statements regarding markets, valuation, product performance, and the potential exchange uplisting are not guarantees of future results. Preliminary indications of investor interest referenced below are non-binding, and no offer of securities is made except through qualified offering materials.

1. Executive Overview - Our Vision: "Ground Zero" Cellular Wellness

BioScience Health Innovations, Inc. ("BHIC," the "Company," "we") is the public-company platform for Best 365 Labs, a foundational-nutrition and cellular-health company. Our thesis is simple and, we believe, differentiated: almost every health journey begins - or should begin - at the cellular level. We call this "ground zero" cellular wellness. Before a consumer chases a symptom, a diagnosis, or the next trending compound, the highest-leverage intervention is restoring the function of the cell and, in particular, the mitochondria that power it.

We are building the Company to be the first-choice starting point for both consumers and clinics - the on-ramp people reach for at the beginning of a wellness or performance journey, and a credible foundation for the avoidance of chronic disease rather than a reaction to it. Our patent-pending toolbox of mitochondrial and cellular-support products is designed to occupy that "ground zero" position across multiple large, growing categories.

The central value driver of the entire platform is our Mods Max delivery system - a patent-pending, mineral-oxide aqueous delivery system that supports enhanced absorption, small-dose (often 1 mL) formats, and sublingual, oral, and topical delivery of compatible actives and peptides. Mods Max is what allows us to take widely known ingredients - NAD precursors, glutathione, methylene blue, peptides, hormone-support actives - and make them more commercially meaningful and, we believe, more effective through delivery efficiency. It is the system, not the ingredient list, that we regard as our defensible moat.

The first half of 2026 has been deliberately structured as a preparation-for-scale phase. We solidified our supply chain, qualified ingredient vendors, trained internal staff, maintained an active R&D pipeline, separated from the related party that built our initial supply chain, upgraded our accounting and ERP infrastructure to NetSuite, closed our initial Regulation A round (crossing the shareholder threshold needed for a senior-exchange uplist), amended that offering, and engaged specialized advisors to guide our exchange application. We view this work as the foundation on which second-half revenue and bottom-line growth will be built.

A note on year-over-year revenue. For those focused solely on a headline year-over-year revenue comparison being down, we would encourage a deeper look. The first six months were spent intentionally rebuilding the operational base - transitioning off a related-party supply chain, requalifying vendors, upgrading systems, and repositioning the product portfolio toward higher-margin, delivery-differentiated categories - rather than chasing short-term top-line volume through unsustainable discounting. Management is confident that by year-end we will demonstrate both revenue growth and bottom-line (product-margin) growth as these investments convert into scalable sales.

2. The Mods Max System - Our Core Value Driver

Everything in this MD&A ultimately traces back to Mods Max. We have spent a great deal of the last several quarters doing three things: testing the system, educating key industry players on why it is different, and building the product and clinical scaffolding that lets us extend it across categories.

Mods Max is positioned as:

·Patent-pending and exclusive - not available anywhere else, which makes the delivery layer itself the defensible product distinction.

·Enhanced-absorption - we deliberately use "enhanced absorption" language rather than hard multiplier claims, to preserve the platform story while keeping our marketing and compliance posture defensible.

·A small-format formula engine - enabling compact 1 mL and sublingual micro-dose formats that feel like easy, daily, layerable rituals.

·Broad but bounded - a strong fit for peptides, small polar or low-bioavailability actives, mitochondrial stacks, hormone-support formulas, sleep formulas, and topicals; we are transparent that it is not a universal solvent for every compound.

Because Mods Max is a system, its value compounds. Each new category we validate - testosterone support, NAD, glutathione, GLP-1 support, menopause, oral and nasal peptides, and clean skincare - is a new application of the same underlying, patent-protected asset. This is the essence of the shareholder-value case: one moat, many markets.

3. Category Strategy - Markets We Intend to Disrupt

Our strategy is to enter large, fast-growing categories where the incumbent solutions carry friction, risk, or delivery limitations that Mods Max is uniquely positioned to solve. We summarize the primary categories below, with third-party market context to frame the opportunity.

3.1 Testosterone Support - TPrime365.com

The opportunity. The testosterone replacement therapy (TRT) market is estimated at roughly USD 2.1-2.2 billion in 2026 and growing steadily (Mordor Intelligence, The Business Research Company). Broader androgen-replacement estimates run higher - around USD 2.9 billion in 2026 growing at an 8% CAGR (Coherent Market Insights). Critically, the reported market measures only prescribed pharmaceutical TRT; it does not capture the far larger population of men who are hesitant to start injections, cream, or clinic-managed therapy because of concerns about fertility suppression, injection burden, and other side effects.

Our approach - TPrime365.com. TPrime365 is our Mods Max-powered testosterone-support product and community platform. Rather than competing head-to-head as a pharmaceutical, we are building TPrime365.com as a community and education hub where men can learn about a delivery-differentiated, non-injection alternative. Our positioning is that TPrime365, powered by Mods Max, can support healthy testosterone in a way that is as effective as testosterone cream in the results we have observed, without the negative outcomes associated with injections - including the fertility concerns that keep many men from starting therapy in the first place. We have published an initial study describing these results, which anchors our education effort and the community we are building around it.

Why community matters to valuation. The published pharmaceutical TRT figures understate our addressable market because they exclude the "hesitant majority" - men who want the benefit but reject the injection risk profile. If we build a durable, engaged community around TPrime365 and continue to demonstrate that our product delivers comparable results without the downside, we can capture demand that today is either unserved or lost to friction. A recurring-revenue, community-driven direct-to-consumer model in a category anchored by a multi-billion-dollar prescription market, but expanded by the far larger side-effect-averse population, represents meaningful potential lifetime value and pricing power per customer.

3.2 NAD, Glutathione, and the Cellular-Wellness Core

The opportunity. The NAD category is expanding rapidly - NAD+ supplement estimates range from roughly USD 966 million in 2026 (PW Consulting) to a broader NAD products market valued at USD 3.45 billion in 2024 and projected to reach USD 12.2 billion by 2033 at a >Grand View Research). This is the heart of "ground zero" cellular wellness.

Our approach. NAD, glutathione, and methylene blue sit at the center of our foundational stack (including our UCOS system and NeuroPro line). Reduced glutathione and NAC are water-soluble actives well suited to Mods Max liquid and sublingual formats, letting us differentiate on delivery in a category crowded with commodity capsules. We are actively educating the supplement and cellular-wellness space on why Mods Max delivery matters here: the same well-known actives, made more bioavailable and easier to take daily, become a better daily ritual and a stickier product.

3.3 GLP-1 Support - Enhancing and "Locking In" Results

The opportunity. The GLP-1 category is one of the largest growth stories in health. GLP-1 weight-loss agonist estimates run from roughly USD 20+ billion in 2025 toward USD 42-49 billion by 2030 at an >Grand View Research). Tens of millions of users are on or cycling off GLP-1 therapy - and a large share of them are concerned about muscle loss, nutrient gaps, energy, and rebound after they stop.

Our approach. We are not competing with GLP-1 drugs; we are the support layer around them. Our education to GLP-1 users centers on how Mods Max-powered tools (our GLP-1 Activate, Metabolism+, and cellular-support products) can help enhance results while on therapy and lock in results after tapering. The "why" is cellular: GLP-1 users need to protect mitochondrial function, support lean mass and metabolism, and fill micronutrient gaps that appetite suppression can create. The "how" is delivery: Mods Max small-dose, high-absorption formats make it realistic for a GLP-1 user to layer targeted cellular support into a daily routine. As the enormous GLP-1 population continues to grow and cycle, a credible support ecosystem is a large, adjacent, and durable revenue opportunity.

3.4 Menopause - Menopause 365 Support + NeuroPro Memory

The opportunity. The menopause supplement and wellness category is large and growing, with dietary supplements the dominant treatment segment. Menopause-focused market estimates range widely by definition, from roughly USD 1 billion in the narrowly defined menopause-supplement segment (Future Market Insights) to USD 18-19 billion for the broader menopause supplements/wellness market (Straits Research), where dietary supplements command roughly 94% of the treatment share (Fact.MR). Millions of women move through peri-, active, and post-menopause with under-served symptom clusters.

Our approach. We introduced Menopause 365 Support, a Mods Max-enabled 1 mL cellular-foundation format designed to be easy to take daily. We believe it is especially powerful when stacked with NeuroPro Memory, addressing both the cellular-foundation and the cognitive/"brain fog" dimensions that many women report across menopause phases. This stacking strategy - foundation plus targeted support - reflects our broader product architecture of systems and packs rather than one-size-fits-all single products.

3.5 Oral and Nasal Peptides - Powered by Mods Max

The opportunity. The peptide therapeutics market is very large and expanding - estimates cluster around USD 49-54 billion in 2026 with high-single-digit to double-digit CAGRs, and some broader definitions run substantially higher (Mordor Intelligence, The Business Research Company). A defining challenge in the category is delivery - most peptides have historically required injection.

Our approach. We are targeting oral and nasal delivery of popular peptides powered by Mods Max. Peptides are among the best-fit actives for our system, and we believe non-injectable delivery is a structural growth driver for the entire category. We expect this category to continue growing and believe we are positioned - through both our delivery platform and our medical relationships - to take advantage of it and create shareholder value.

3.6 Clean Skincare - Glow + Patent-Pending Red-Light Topical Spray

The opportunity. The clean/natural skincare category is large and growing faster than conventional beauty: natural skincare estimates run from roughly USD 9 billion (Global Growth Insights) to USD 25-48 billion depending on definition (Research and Markets, Mordor Intelligence), with the tightly defined "clean beauty" segment growing at roughly 14% CAGR (Stellar Market Research).

Our approach. Our Glow product has been very well accepted and continues to grow. Building on that momentum, we capitalized on one of our patents by teaming with a distribution group with 5,500 storefronts to introduce a patent-pending red-light topical spray powered by Mods Max and formulated with USP methylene blue. We believe Mods Max positions us distinctively in clean skincare: enhanced-absorption, antioxidant, brightening, and calming benefits from a delivery system competitors cannot replicate. Even a low-single-digit share of a clean-skincare market measured in the tens of billions represents a material revenue opportunity, and the 5,500-storefront distribution relationship gives us a concrete, near-term path to capture it at retail scale.

4. Medical Advisory and Clinical Credibility - Happy MD and Dr. Steve Warren

A key part of disrupting the peptide and testosterone markets is credibility with clinicians and consumers. Two assets underpin this:

·Happy MD agreement. Our agreement with Happy MD provides a physician-supervised access pathway that lets us pursue the peptide and testosterone-support categories responsibly and at scale.

·Medical advisory team led by Dr. Steve Warren, MD. Our medical director anchors our clinical positioning and separates us from lifestyle-only brands. Together with our medical director, we have helped publish two books on Amazon to educate both consumers and physicians on our cutting-edge, cellular-first approach.

This medical scaffolding is what allows us to be a higher-trust, medically aligned partner for prescribers and clinics - reinforcing our goal of being the "ground zero" starting point for clinics, not just consumers.

5. Distribution, Channel, and Partnership Expansion

·Amazon - Rebelution / Growvana initiative. We continue to build our Amazon presence through the Rebelution/Growvana initiative. Amazon has recently begun requiring additional certifications for products in our categories; we are actively completing that certification work, which we view as a barrier to entry that favors compliant, well-capitalized sellers. As we complete it, we are expanding our product footprint and sales on the platform.

·Retail distribution - clean skincare. The 5,500-storefront distribution relationship for our red-light topical spray extends Mods Max into physical retail.

·Spa / select-label distribution. We are working on adding a select label for spa distribution with reach into 5,000-plus outlets, packaged around clinic- and reseller-friendly starter-pack economics.

·Strategic co-brand opportunities. We continue to evaluate strategic co-brand deals with players such as The Wellness Company (TWC), 10X, and others, where Mods Max can serve as the differentiated delivery layer inside a partner's brand.

6. Closed AI Investment - Combating Misinformation

We made a major investment in a closed (private) AI system to help us educate and reinforce our approach with consumers and wholesalers. The cellular-wellness, peptide, and hormone categories are unusually prone to misinformation, and a controlled, on-brand AI tool lets us deliver consistent, compliant, science-forward education at scale - helping customers and partners cut through the noise while keeping our messaging aligned with our compliance posture. We view this as both a customer-acquisition asset and a moat around the credibility of our education effort.

7. Operational Foundation Built in H1 2026

The first six months were dedicated to building the base required to scale responsibly:

·Supply chain solidified. We separated from the related party that built our initial supply chain and stood up an independent, requalified vendor base - improving both governance optics and long-term margin control.

·Ingredient vendors qualified. We took ownership of supplier qualification, true-manufacturer identification, and third-party lot-release testing, making quality a company-owned process rather than a pass-through reliance on supplier labels.

·Internal staff trained and an active R&D effort maintained across our category pipeline.

·NetSuite ERP upgrade. We upgraded our accounting and operating system to NetSuite in preparation for scale. Benefits include: manufacturing-grade perpetual inventory and more accurate COGS; a single source of truth across accounting, inventory, and order management; real-time financial visibility and faster close; stronger internal controls and audit-readiness appropriate for a senior-exchange issuer; and the scalability to support multi-channel (DTC, Amazon, retail, spa, wholesale) growth without re-platforming. In short, NetSuite gives us the financial-reporting discipline and inventory accuracy a public, exchange-listed company is expected to have.

8. Capital Markets and Uplisting Progress

We undertook this operational rebuild specifically to prepare BHIC to uplist to a major exchange, and we are pleased to report that the process is progressing nicely.

·Advisor engaged. We have engaged Donohoe to help navigate the uplisting process, including pre-application strategy, exchange liaison, and application-package review.

·Reg A round completed. We completed a $1.00 Regulation A round, which brought us over the 400-shareholder threshold required for the uplist.

·Amended offering. We amended the offering to $4.50 per share and plan to raise up to $5 million. We have seen very positive initial interest and, at this point, expect to wrap up this additional offering quickly and then make application to a senior exchange. (Indications of interest are non-binding and do not constitute an offer; any securities are offered only through qualified offering materials.)

·Independent board. We have identified the initial independent board members required for senior-exchange governance, including candidates suited to chair key committees, with appointments structured to take effect in connection with the uplisting.

This capital-markets work is designed to move BHIC from OTC visibility to a more institutional public-market posture - expanding investor access, reducing perceived governance risk, and supporting a higher valuation multiple on both our revenue and our intellectual-property assets.

9. Valuation Perspective - One Moat, Many Markets

Management believes the appropriate way to think about BHIC's potential valuation is not as a single-product supplement company, but as a patent-pending delivery system (Mods Max) applied across a portfolio of large, growing categories. The combined third-party-estimated size of the categories we are entering is substantial:

Category	Illustrative 2026 Market Size (third-party estimates)	Growth Signal
Testosterone / androgen replacement	~$2.1B (TRT) to ~$2.9B (androgen) (Mordor, Coherent)	~4-8% CAGR, plus large unserved side-effect-averse population
NAD / cellular wellness	~$1.0B to $3.5B+ depending on definition (PW Consulting, Grand View)	~15% CAGR
GLP-1 support (adjacent to GLP-1 drug market)	GLP-1 drug market >Grand View)	~18% CAGR
Menopause	~$1B (supplements, narrow) to ~$18-19B (broad) (FMI, Straits)	~5.5-6% CAGR, supplements ~94% of treatment
Peptide therapeutics	~$49-54B (Mordor, TBRC)	~7-11% CAGR; oral/nasal delivery a key driver
Clean / natural skincare	~$9B to ~$48B depending on definition (Global Growth Insights, Mordor)	~7% CAGR; clean beauty ~14% CAGR

The point is not that we will capture all of these markets - it is that a single, patent-protected delivery system gives us a credible, differentiated entry into each of them. The biggest value driver is Mods Max itself: the more categories in which we validate it (with published data, medical endorsement, retail distribution, and community), the more the system is worth independent of any single SKU. Our biggest lever on shareholder value is therefore continued proof - clinical, commercial, and distributional - that Mods Max works and travels across categories.

10. Results of Operations and Outlook

For the six months ended June 30, 2026, headline revenue reflects the deliberate transition described above: a rebuild of the supply chain and vendor base, separation from a related party, a shift away from margin-eroding discounting, and repositioning toward higher-margin, delivery-differentiated categories. We caution readers against reading a year-over-year top-line decline in isolation. The relevant question is whether the Company exits this period with a stronger, more scalable, higher-margin, and better-governed system - and management believes it does.

Looking to the second half of 2026, management is confident that the combination of (i) completed operational and ERP infrastructure, (ii) an expanding, certified Amazon and retail footprint, (iii) new category launches across testosterone support, GLP-1 support, menopause, peptides, and clean skincare, (iv) medical-advisory-backed credibility, and (v) the capital and visibility from a completed offering and prospective uplisting, positions BHIC to demonstrate both revenue growth and bottom-line product-margin growth by year-end.

11. Forward-Looking Statements and Disclaimers

This MD&A contains forward-looking statements regarding our strategy, markets, products, offering, and potential exchange uplisting. Actual results may differ materially. Market-size figures are third-party estimates cited for context and vary by source and definition. Product statements are not intended as disease-treatment or cure claims; certain products carry clinician-review and other cautions where appropriate. Indications of investor interest are non-binding, and no securities are offered except through qualified offering materials. Completion of the offering and any uplisting is subject to market, regulatory, and exchange conditions and is not assured.

Sources for market context: Mordor Intelligence; The Business Research Company; Coherent Market Insights; PW Consulting; Grand View Research - NAD; Grand View Research - GLP-1; Future Market Insights - Menopause; Straits Research - Menopause; Fact.MR - Menopause; Mordor Intelligence - Peptides; The Business Research Company - Peptides; Global Growth Insights - Natural Skincare; Mordor Intelligence - Natural Skincare; Research and Markets - Natural Skincare; Stellar Market Research - Clean Beauty

OFF-BALANCE SHEET ARRANGEMENTS

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.